Interchange Capital Partners LLC Has $49.76 Million Position in Semler Scientific Inc. $SMLR

Interchange Capital Partners LLC reduced its holdings in shares of Semler Scientific Inc. (NASDAQ:SMLR) by 0.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,283,377 shares of the company’s stock after selling 1,198 shares during the period. Semler Scientific comprises 49.2% of Interchange Capital Partners LLC’s portfolio, making the stock its biggest position. Interchange Capital Partners LLC owned about 0.09% of Semler Scientific worth $49,764,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Semler Scientific by 226.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 158,576 shares of the company’s stock worth $5,740,000 after acquiring an additional 109,951 shares during the last quarter. Deltec Asset Management LLC lifted its stake in shares of Semler Scientific by 112.0% during the 2nd quarter. Deltec Asset Management LLC now owns 100,932 shares of the company’s stock worth $3,910,000 after acquiring an additional 53,332 shares during the last quarter. Generali Asset Management SPA SGR bought a new stake in shares of Semler Scientific during the 2nd quarter worth approximately $2,712,000. Pacer Advisors Inc. bought a new stake in shares of Semler Scientific during the 1st quarter worth approximately $1,874,000. Finally, Royal Bank of Canada lifted its stake in shares of Semler Scientific by 101.2% during the 1st quarter. Royal Bank of Canada now owns 43,977 shares of the company’s stock worth $1,592,000 after acquiring an additional 22,123 shares during the last quarter. 49.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on SMLR. Maxim Group decreased their target price on Semler Scientific from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, September 19th. Benchmark decreased their target price on Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Semler Scientific in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald decreased their target price on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $74.25.

Semler Scientific Trading Down 2.5%

Shares of NASDAQ:SMLR opened at $25.68 on Wednesday. Semler Scientific Inc. has a 12-month low of $23.51 and a 12-month high of $81.56. The business’s fifty day simple moving average is $30.51 and its 200-day simple moving average is $34.58. The company has a market capitalization of $388.80 million, a PE ratio of 10.57 and a beta of 1.41. The company has a current ratio of 0.60, a quick ratio of 0.58 and a debt-to-equity ratio of 0.25.

Semler Scientific (NASDAQ:SMLR) last announced its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $5.31. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.The business had revenue of $8.22 million for the quarter, compared to the consensus estimate of $8.10 million.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.